Two FDA-approved methods are currently used to determine HER2 status for trastuzumab therapy in breast cancers—immunohistochemical (IHC) analysis of HER2 protein expression and fluorescence in situ hybridization (FISH) analysis of HER2 gene amplification of tumor biopsy material [6]. The gene discussed is ERBB2; the disease is breast cancer.